COVID-19 Evidence Reviews
as of 8/13/20
menu
 
 

Candidate Therapeutics
 
= living review
= draft/preprint   |  
= meets mimimum quality standards   |  

A review with this mark was peer-reviewed, described systematic search and study selection, and included critical appraisal of primary studies.
latest update
report
select
8/3/20
Putman M, Chock YPE, Tam H, et al. | Arthritis Rheumatol
Aim: To identify and summarize research that describes the use of antirheumatic disease therapies for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
8/2/20
Volpe M, Battistoni A | Int J Cardiol
Aim: To review the evidence on the potential role of renin-angiotensin system inhibitors, specifically angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, with regard to COVID-19 disease and mortality.
CANDIDATE THERAPEUTICS
8/1/20
Siemieniuk RAC, Bartoszko JJ, Ge L, et al. | BMJ
Aim: To compare the effects of treatments for coronavirus disease 2019 (covid-19).
CANDIDATE THERAPEUTICS
8/1/20
Hasan SS, Capstick T, Ahmed R, et al. | Expert Rev Respair Med
Aim: To review ARDS-associated mortality and the potential role of systemic corticosteroids in COVID-19 patients.
CANDIDATE THERAPEUTICS
7/30/20
Musa A, Pendi K, Hashemi A, et al. | West J Emerg Med
Aim: To review the evidence on the use of remdesivir for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
7/28/20
Cortegiani A, Ippolito M, Greco M, et al. | Pulmonology
Aim: To describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy. and safety.
CANDIDATE THERAPEUTICS
7/28/20
Haiduc AA, Alom S, Melamed N, Harky A | J Card Surg
Aim:  To examine the literature evidence behind using extracorporeal membrane oxygenation in COVID?19 patients in a systematic review manner.
CANDIDATE THERAPEUTICS
7/28/20
Lan S, Lai C, Huang H, et al. | Int J Antimicrob Agents
Aim: To assess the efficacy of tocilizumab for the treatment of severe coronavirus disease-2019 (COVID-19).
CANDIDATE THERAPEUTICS
7/25/20
Solis-Garcia Del Pozo J, Galindo MF, Nava E, et al. | Eur Rev Med Pharmacol Sci
Aim: To review the evidence on the role of IL-6 in treating COVID-19.
CANDIDATE THERAPEUTICS
7/24/20
Venkatesulu BP, Chandrasekar VT, Giridhar P, et al. | J Med Virol
Aim: To do a systematic review and critical appraisal of the ongoing clinical trials that are assessing various therapeutic interventions against SARS-CoV-2 with an aim to provide insight into the various interventions tested, clinical rationale, geographical distribution of the trials as well as the endpoints assessed in the studies.
UPDATED
CANDIDATE THERAPEUTICS
7/21/20
Vidali S, Morosetti D, Cossu E, et al. | ERJ Open Res
Aim: To highlight the correlation between elevated D-dimer (an indirect thrombosis marker) and the increased rate of poor prognosis-associated conditions, and to introduce D-dimer-labelled anticoagulant administration as a potentially useful tool to prevent complications and positively influence coronavirus disease 2019 (COVID-19) course.
CANDIDATE THERAPEUTICS
7/20/20
Cortegiani A, Ingoglia G, Ippolito M, et al. | J Crit Care
Aim: To evaluate the efficacy and safety of chloroquine and chloroquine-related formulations in patients with SARS-CoV-2 pneumonia and articles describing related in-vitro studies.
UPDATED
CANDIDATE THERAPEUTICS
7/17/20
Greco A, Buccheri S, D'Arrigo P, et al. | Eur Heart J Cardiovasc Pharmacother
Aim: To review the evidence on the impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the clinical outcomes of COVID-19 patients.
UPDATED
CANDIDATE THERAPEUTICS
7/15/20
Chandrasekar VT, Venkatesalu B, Patel HK, et al. | J Med Virol
Aim: To assess if any intervention provides mortality benefit, other clinically relevant outcomes and also ascertain the safety profile.
UPDATED
CANDIDATE THERAPEUTICS
7/11/20
Piechotta V, Chai KL, Valk SJ, et al. | Cochrane Database Syst Rev
Aim: To assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID?19.
UPDATED
CANDIDATE THERAPEUTICS
7/10/20
Yu C, Kang L, Chen J, et al. | Int Immunopharmacol
Aim: To recapitulate relevant studies to evaluate the safety, efficacy, tolerability and treatment-related outcomes of type I IFNs for coronavirus infection in clinical practice, with expectation to provide more robust evidence whether IFNs should be served as first-line agents for coronavirus infection, including the SARS-CoV-2.
CANDIDATE THERAPEUTICS
7/8/20
Sun M, Xu Y, He H, et al. | Int J Infect Dis
Aim: To explore the effectiveness of treatment and predict the potential effect of convalescent plasma for COVID-19.
CANDIDATE THERAPEUTICS
7/8/20
Zhu R, Gao Y, Robert S, et al. | J Transl Med
Aim: To summarize the characteristics of clinical trials for COVID-19.
CANDIDATE THERAPEUTICS
7/6/20
Xiong X, Wang P, Su K, et al. | Pharmacol Res
Aim: To evaluate the current clinical evidence on Chinese herbal medicine for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
7/3/20
Huang D, Yu H, Wang T, et al. | J Med Virol
Aim: To evaluate the efficacy and safety of umifenovir in COVID?19.
CANDIDATE THERAPEUTICS
7/1/20
Alizadeh F, Khodavandi A | IEEE Trans Nanobioscience
Aim: To summarize the available evidence on the efficacy of nanoscale materials against coronaviruses in vitro and in animal models.
CANDIDATE THERAPEUTICS
6/23/20
Lu S, Zhou Q, Huang L, et al. | Ann Transl Med
Aim: To review the evidence on the use of glucocorticoids in treating COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
6/23/20
Zhang J, Yang Y, Yang N, et al. | Ann Transl Med
Aim: To explore the clinical effectiveness and safety of IVIG in the treatment of children with severe COVID-19.
UPDATED
CANDIDATE THERAPEUTICS
6/23/20
Wang J, Tang Y, Ma Y, et al. | Ann Transl Med
Aim: To evaluate the efficacy and safety of antibiotic agents in children with COVID-19, as well as to introduce the present situation of antibiotics use and bacterial coinfections in COVID-19 patients. 
UPDATED
CANDIDATE THERAPEUTICS
6/23/20
Shi Q, Zhou Q, Wang X, et al. | Ann Transl Med
Aim: To assess the potential effectiveness and safety of antiviral agents for COVID-19 in children. 
UPDATED
CANDIDATE THERAPEUTICS
6/20/20
Maldonado E, Tao D, Mackey K | J Gen Intern Med
Aim: To synthesize evidence on thromboembolism incidence and outcomes with antithrombotic therapies in COVID-19.
UPDATED
VA ESP
CANDIDATE THERAPEUTICS
6/17/20
Di Lorenzo G, Di Trolio R, Kozlakidis Z, et al. | Crit Rev Oncol Hematol
Aim: To review the evidence on the clinical outcomes of COVID-19-positive patients and the possible interactions between drugs used in experimental therapy of COVID-19 and commonly used antineoplastic drugs.
CANDIDATE THERAPEUTICS
6/14/20
Heidary F, Gharebaghi R | J Antibiot (Tokyo)
Aim: To summarize the antiviral effects of ivermectin by reviewing available in vivo and in vitro studies over the past 50 years.
CANDIDATE THERAPEUTICS
6/13/20
Zhu T, Xu A, Bai X, et al. | Zhonghua Wei Zhong Bing Ji Jiu Yi Xue
Aim: To systematically review evidence for the effect of convalescent plasma and immunoglobulin on treatment of severe acute respiratory syndrome (SARS), and further provide advice on the treatment of coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
6/9/20
Patel TK, Barvaliya M, Kevadiya BD, et al. | J Neuroimmune Pharmacol
Aim: To find out early trends of mortality in COVID-19 patients treated with hydroxychloroquine based on published literature.
CANDIDATE THERAPEUTICS
6/9/20
Nasir M, Talha KA, Islam T, et al. | Mymensingh Med J
Aim:  To evaluate the available evidence on efficacy, safety to identify any promising role for compassionate use of remdesivir in patient suffered for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as re-purposeful use. 
CANDIDATE THERAPEUTICS
6/8/20
Lima WG, Brito J, Overhage J, et al. | Arch Virol
Aim: To describe the drug repositioning strategy against SARS-CoV-2 and to discuss the clinical impact of this approach in the current pandemic context. 
CANDIDATE THERAPEUTICS
6/5/20
Bhagavathula AS, Aldhaleei WA, Rovetta A, et al. | Cureus
Aim: To extract and summarize information on potential vaccines and therapeutic agents against COVID-19 at different stages of clinical trials from January to March 2020.
CANDIDATE THERAPEUTICS
6/4/20
Ye Z, Wang Y, Colunga-Lozano LE, et al. | CMAJ
Aim: To examine the impact of corticosteroids in COVID-19 and related severe acute respiratory illnesses to support a guideline for managing COVID-19.
CANDIDATE THERAPEUTICS
6/3/20
Liu W, Zhou P, Chen K, et al. | CMAJ
Aim: To support the development of a COVID-19 management guideline by reviewing evidence that addressed the benefits and harms of 7 antiviral treatments for COVID-19.
CANDIDATE THERAPEUTICS
5/28/20
Das S, Bhowmick S, Tiwari S, et al. | Clin Drug Investig
Aim: To systematically review the therapeutic role of HCQ in COVID-19 from the available literature.
CANDIDATE THERAPEUTICS
5/27/20
Hernandez AV, Roman YM, Pasupuleti V, et al. | Ann Intern Med
Aim: To summarize evidence about the benefits and harms of hydroxychloroquine or chloroquine for the treatment or prophylaxis of coronavirus disease 2019 (COVID-19).
CANDIDATE THERAPEUTICS
5/27/20
Fajgenbaum DC, Khor JS, Gorzewski A, et al. | Infect Dis Ther
Aim: To systematically evaluate the treatments adminstered to COVID-19 patients.
UPDATED
CANDIDATE THERAPEUTICS
5/26/20
Rodrigo C, Fernando SD, Rajapakse S | Clin Microbiol Infect
Aim: To summarize evidence from human clinical studies for using HCQ or CQ as antiviral agents for any viral infection.
CANDIDATE THERAPEUTICS
5/23/20
Ang L, Song E, Lee HW, et al. | J Clin Med
Aim: To evaluate the effectiveness and adverse events of herbal medicines for the treatment of COVID-19.
CANDIDATE THERAPEUTICS
5/22/20
Devasenapathy N, Ye Z, Loeb M, et al. | CMAJ
Aim: To review the safety and efficacy of convalescent plasma in severe coronavirus disease 2019 (COVID-19) patients for guideline development
CANDIDATE THERAPEUTICS
5/21/20
Antwi-Amoabeng D, Kanji Z, Ford B, et al. | J Med Virol
Aim: To summarize the baseline characteristics of COVID-19 patients who received tocilizumab in order to identify nuanced predictors of response to therapy and other clinical outcomes.
CANDIDATE THERAPEUTICS
5/19/20
Sachdeva M, Mufti A, Maliyar K, et al. | J Am Acad Dermatol
Aim: To conduct a systematic review of previously reported cases of psoriasis onset, exacerbation, or relapse after HCQ treatment.
CANDIDATE THERAPEUTICS
5/15/20
Zhang X, Yu J, Pan L, et al. | Pharmacol Res
Aim: To (1) determine whether use of ACRI/ARB is associated with an increase in likelihood of viral infectivity; (2) to investigate whether there are differences in severity and mortality between ACRI/ARB users and non- ACRI/ARB users; (3) and, in particular, to evaluate whether ACRI/ARB exposure was associated with a lower risk of mortality when compared to non-ACRI/ARB antihypertensive drug exposure. 
CANDIDATE THERAPEUTICS
5/14/20
Gbinigie K, Frie K | BJGP Open
Aim: To review the evidence for the effectiveness and safety of azithromycin in treating COVID-19.
CANDIDATE THERAPEUTICS
5/12/20
Chowdhury MS, Rathod J, Gernsheimer,J | Acad Emerg Med
Aim: To examine the evidence on chloroquine and hydroxychloroquine as treatments for COVID-19.
CANDIDATE THERAPEUTICS
5/12/20
Singh AK, Singh A, Shaikh A, et al. | Diabets Metab Syndr
Aim: To review existing literature and relevant websites regarding these drugs and COVID-19, adverse effects related to drugs, and related guidelines.
CANDIDATE THERAPEUTICS
5/12/20
Rajendran K, Narayanasamy K, Rangarajan J, et al. | J Med Virol
Aim: To evaluate the effectiveness of CPT therapy in COVID-19 patients based on the publications reported till date.
CANDIDATE THERAPEUTICS
5/12/20
Veronese N, Demurtas J, Yang L, et al. | Front Med
Aim: To investigate the effectiveness of glucocorticoid therapy in patients with COVID-19.
CANDIDATE THERAPEUTICS
5/11/20
Patil VM, Singhal S, Masand N | Life Sci
Aim: To review the evidence on the mechanism of action, safety (side effects, adverse effects, toxicity) and details of clinical trials for chloroquine and hydroxychloroquine.
CANDIDATE THERAPEUTICS
5/10/20
Liu M, Gao Y, Yuan Y, et al. | Pharmacol Res
Aim: To assess the efficacy and safety of Integrated Traditional Chinese and Western Medicine to corona virus disease 2019 (COVID-19). 
CANDIDATE THERAPEUTICS
5/10/20
Jankelson L, Karam G, Becker ML, et al. | Heart Rhythm
Aim: To conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine.
CANDIDATE THERAPEUTICS
5/8/20
Li Z, Wang X, Cao D, et al. | Drug Discov Ther
Aim: To critically assess the potential anti-coronavirus effect of remdesivir on COVID-19 and other coronaviruses based on the most up-to-date evidence.
CANDIDATE THERAPEUTICS
5/5/20
Li H, Chen C, Hu F, et al. | Leukemia
Aim: To determine safety and efficacy of corticosteroids in SARS-CoV-2, SARS-CoV, and MERS-CoV infections.
CANDIDATE THERAPEUTICS
5/2/20
Chowdhury M, Rathod J, Gernsheimer J | Acad Emerg Med
Aim: To review literature currently available regarding the clinical use of CQ and HCQ as treatment in COVID-19 patients in an effort to catalog their recommendations and assess drug efficacy.
CANDIDATE THERAPEUTICS
4/30/20
Zhong H, Wang Y, Zhang Z, et al. | Pharmacol Res
Aim: To evaluate the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients.
CANDIDATE THERAPEUTICS
4/27/20
Halpin D, Singh D, Hadfield RM | Eur Respir J
Aim: To evaluate whether pre-morbid use or continued administration of inhaled steroids is a risk factor for adverse outcomes in acute respiratory infections due to COVID-19, SARS or MERS. 
WHO COLLABORATIVE
CANDIDATE THERAPEUTICS
4/21/20
Yousefifard M, Zali A, Mohamed A, et al. | Arch Acad Emerg Med
Aim: To evaluate the efficacy of antiviral therapies in treatment of COVID-19.
CANDIDATE THERAPEUTICS
4/21/20
Alzghari SK, Acuna VS | J Clin Virol
Aim: To evaluate outcomes associated with TCZ treatment in patients with COVID-19.
CANDIDATE THERAPEUTICS
4/17/20
Tobaigy M, Qashgary M, Al-Dahery S, et al. | Infect Prev Pract
Aim: To report any evidence of therapeutics used for the management of COVID-19 patients in clinical practice since the emergence of the virus.
CANDIDATE THERAPEUTICS
4/17/20
Sarma P, Kaur H, Kumar H, et al. | J Med Virol
Aim: To examine the evidence for the safety and efficacy of hydroxycholorquine in COVID-19.
CANDIDATE THERAPEUTICS
4/14/20
Shah S, Das S, Jain A, et al. | Int J Rheum Dis
Aim: To systematically review the role of CQ and HCQ in preventing the spread of COVID-19.
CANDIDATE THERAPEUTICS
4/14/20
Yang Z, Liu J, Zhou Y, et al. | J Infect
Aim: To further evaluate the influence of corticosteroids on patients with coronavirus infection.
CANDIDATE THERAPEUTICS
4/10/20
Aminjafari A, Ghasemi S | Int Immunopharmacol
Aim: To evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV.
CANDIDATE THERAPEUTICS
4/9/20
Gbinigie K, Kerstin F | BJGP Open
Aim: To establish the current evidence for the effectiveness of CQ and HCQ in treating COVID-19.
CANDIDATE THERAPEUTICS
3/29/20
Lin A, Hye W, Jun Y, et al.  | Integr Med Res
Aim: To summarize and analyze the herbal formulae provided by the guidelines for their pattern identifications (PIs) and compositions of herbs to treat patients with COVID-19
CANDIDATE THERAPEUTICS
2/25/20
Rios P, Radhakrishnan A, Antony J, et al. | Public Health Agency of Canada
Aim: To identify safe and effective medical countermeasures (e.g., antivirals/antibodies) to address the current outbreak of a novel coronavirus (COVID-19)
CANDIDATE THERAPEUTICS
2/14/20
Zhang L, Liu Y | J Med Virol
Aim: To summarize therapeutic options available for the treatment of COVID-19
CANDIDATE THERAPEUTICS
2/1/20
Prajapat M, Sarma P, Shekhar N, et al. | Indian J Pharmacol
Aim: To describe protein structures that are potential targets for the development of CoV therapies
CANDIDATE THERAPEUTICS